1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9): 624-639. doi:10.1038/s41571-023-00798-3
2. Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693. doi:10.1016/j.canep. 2024.102693
3. Rodak O, Peris-Diaz MD, Olbromski M, Podhorska-Okolow M, Dziegiel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers (Basel). 2021;13(18):4705. doi:10.3390/cancers13184705
4. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-594. doi:10.4065/83.5.584
5. Arbour KC, Riely GJ. Systemic Therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764-774. doi:10.1001/jama.2019.11058
6. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99-108. doi:10.6004/jnccn.2009.0009
7. Wagland R, Richardson A, Ewings S, et al. Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of life and associated supportive care: a cross-sectional survey. Support Care Cancer. 2016;24(12):4901-4911. doi:10.1007/s00520-016-3346-4
8. Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol. 2022;19(11):681-697. doi:10.1038/s41571-022-00685-3
9. Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 17 20 03;1(1):46. doi:10.1186/1477-7525-1-46
10. Llopis-Salvia P, Sarrio-Montes G, Garcia-Llopis P, Bargues-Ruiz A. Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting. J Oncol Pharm Pract. 2010;16(4):256-261. doi:10.1177/1078155209355848
11. SjOgren K, Jacobsen KA, GrOnberg BH, Halvorsen TO. Timing of severe toxicity from chemotherapy in patients with lung cancer. Anticancer Res. 2020;40(11):6399-6406. doi:10.21873/anticanres.14661
12. Kalsi T, Babic-Illman G, Fields P, et al. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer. 2014;111(12):2224-2228. doi:10.1038/bjc.2014.496
13. Boguszewicz L. Predictive biomarkers for response and toxicity of induction chemotherapy in head and neck cancers. review. Front Oncol. 2022;12:900903. doi:10.3389/fonc.2022.900903
14. Kim J, Hurria A. Determining chemotherapy tolerance in older patients with cancer. J Natl Compr Canc Netw. 2013;11(12):1494-1502. doi:10. 6004/jnccn.2013.0176
15. Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187-1196. doi:10.1016/j.clnu.2017.06.017
16. Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(1):27-35. doi:10.1007/s13539-011-0022-x
17. Ruan GT, Ge YZ, Xie HL, et al. Association between systemic inflammation and malnutrition with survival in patients with cancer sarcopenia-a prospective multicenter study. original research. Front Nutr. 2021;8:811288. doi:10.3389/fnut.2021.811288
18. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409-1412. doi:10.1038/bjc.2014.90
19. Perez-Pitarch A, Guglieri-Lopez B, Nacher A, Merino V, Merino-Sanjuan M. Impact of undernutrition on the pharmacokinetics and pharmacodynamics of anticancer drugs: a literature review. Nutr Cancer. 2017;69(4):555–563. doi:10.1080/01635581.2017.1299878
20. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48. doi:10.1016/j.clnu.2016. 07.015
21. Ikeda S, Yoshioka H, Ikeo S, et al. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status. BMC Cancer. 2017;17(1):797. doi:10.1186/s12885-017-3814-3
22. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90(10):1905-1911. doi:10.1038/sj.bjc.6601781
23. Lin T, Yang J, Hong X, Yang Z, Ge T, Wang M. Nutritional status in patients with advanced lung cancer undergoing chemotherapy: a prospective observational study. Nutr Cancer. 2020;72(7):1225-1230. doi:10.1080/01635581.2019.1675720
24. Nadler E, Arondekar B, Aguilar KM, et al. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. J Cancer Res Clin Oncol. 2021;147(3):671-690. doi:10.1007/s00432-020-03414-4
25. Lis CG, Gupta D, Lammersfeld CA, Markman M, Vashi PG. Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature. Nutr J. 2012;11(1):27. doi:10.1186/1475-2891-11-27
26. Adam R, Haileselassie W, Solomon N, et al. Nutritional status and quality of life among breast Cancer patients undergoing treatment in Addis Ababa, Ethiopia. BMC Womens Health. 2023;23(1):428. doi:10. 1186/s12905-023-02585-9
27. Zhang Y, Kong FF, Zhu ZQ, Shan HX. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy. BMC Cancer. 2023;23(1):225. doi:10. 1186/s12885-023-10682-z
28. Gouez M, Delrieu L, Bouleuc C, Girard N, Raynard B, Marchal T. Association between nutritional status and treatment response and survival in patients treated with immunotherapy for lung cancer: a retrospective french study. Cancers (Basel). 2022;14(14):3439. doi:10. 3390/cancers14143439
29. Park S, Park S, Lee SH, et al. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. Korean J Intern Med. 2016;31(6):1140-1149. doi:10.3904/kjim.2015.062
30. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10:50. doi:10.1186/1471-2407-10-50
31. Karabulut S, Dogan I, Usul Afsar C, et al. Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. J Oncol Pharm Pract. 2021;27(6):1357-1363. doi:10.1177/1078155220959427
32. Dunne RF, Loh KP, Williams GR, Jatoi A, Mustian KM, Mohile SG. Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers (Basel). 2019;11(12):1861. doi:10.3390/cancers11121861
33. Papadopoulos E, Irving BA, Brown JC, et al. Sarcopenia and cachexia in older patients with cancer: pathophysiology, diagnosis, impact on outcomes, and management strategies. Drugs Aging. 2025;42(12):1113-1142. doi:10.1007/s40266-025-01252-y
34. Ryan AM, Power DG, Daly L, Cushen SJ, Ni Bhuachalla E, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75(2):199-211. doi:10.1017/S002966511500419X
35. Blohmer JU, Dunst J, Harrison L, et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology. 2005;68 Suppl 1:12-21. doi:10.1159/000083129
36. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15(6):979-986. doi:10.1093/annonc/mdh235
37. Idasiak-Piechocka I, Lewandowski D, Swigut W, et al. Effect of hypoalbuminemia on drug pharmacokinetics. review. Front Pharmacol. 2025;16:1546465. doi:10.3389/fphar.2025.1546465
38. Gandia P, Decheiver S, Picard M, Guilhaumou R, Baklouti S, Concordet D. Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades. Antibiotics (Basel). 2023;12(3):515. doi:10.3390/antibiotics12030515
39. Polanski J, Chabowski M, Swiatoniowska-Lonc N, et al. Relationship between nutritional status and clinical outcome in patients treated for lung cancer. Nutrients. 2021;13(10):3332. doi:10.3390/nu13103332
40. Trestini I, Sperduti I, Sposito M, et al. Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. ESMO Open. 2020;5(3):e000689. doi:10.1136/esmoopen-2020-000689